DBV Technologies Set to Report Third Quarter 2026 Financial Results
News related to:DBV Technologies · 2 min read
DBV Technologies, a late-stage biopharmaceutical company based in Châtillon, France, is set to report its third quarter 2026 financial results and provide a business update on October 28, 2026. The company will host a conference call and live audio webcast at 5:00 p.m. ET, offering insights into its performance and strategic direction.
The conference call will be accessible via the following numbers: - United States: +1-877-344-8082 - International: +1-213-992-4618
Participants are asked to dial in and request to join the DBV Technologies Third Quarter 2026 Results call. A live webcast of the call will also be available on the Company’s website, accessible through the Events section.
DBV Technologies is dedicated to developing treatment options for food allergies and other immunologic conditions. The company’s primary focus is on the VIASKIN® patch technology, which is designed to introduce microgram amounts of a biologically active compound through the skin to re-educate the immune system and desensitize individuals to allergens. The VIASKIN® Patch is currently being investigated for its efficacy in treating peanut allergies in toddlers and children aged 4 to 7.
The company’s food allergy programs include ongoing clinical trials of the VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). These trials are part of the company’s broader mission to provide innovative treatment options for food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergens. EPIT is a new class of non-invasive treatment that seeks to leverage the skin’s immune tolerizing properties to achieve its therapeutic goals.
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT, CUSIP: 23306J309).